How to Help Your Patients Save Money on Dihydroergotamine: A Provider's Guide to Savings Programs

Dihydroergotamine (DHE) is one of the most effective acute migraine treatments available — and one of the most expensive. With generic injection prices ranging from $260 to $2,900 and brand-name Trudhesa costing over $4,600 per supply, cost is a real barrier to adherence. For many patients, the question isn't whether DHE works — it's whether they can afford to keep using it.

This guide walks providers through the savings programs, discount strategies, and therapeutic alternatives that can help your patients stay on treatment. For more provider tools, visit Medfinder for Providers.

What Your Patients Are Actually Paying

The cost landscape for Dihydroergotamine is complicated because it comes in multiple formulations from different manufacturers, each with vastly different pricing:

• Generic DHE injection (1 mg/mL): $260–$400 with discount coupons, up to $2,900 without
• D.H.E. 45 (brand injection): Approximately $12,400 for 10 mL
• Migranal nasal spray: $500–$900
• Trudhesa nasal spray: Approximately $4,600 for 8 sprays
• Brekiya subcutaneous injection: Newer formulation by Amneal Pharmaceuticals, pricing varies

Many patients don't realize the price varies this dramatically between formulations. A quick conversation about which form they're using — and whether an alternative formulation could work — can save them thousands.

Manufacturer Savings Programs

The most impactful savings tool for brand-name DHE formulations is the manufacturer copay card. These programs can reduce out-of-pocket costs to near zero for eligible patients.

Trudhesa Direct Savings Program

Impel Pharmaceuticals offers the Trudhesa Direct Savings Program for commercially insured patients. Key details:

• Eligible patients may pay as little as $0 per prescription
• Available for patients with commercial (private) insurance
• Not available for Medicare, Medicaid, Tricare, or other government insurance
• Enrollment: Call 1-800-589-0841 or visit the Trudhesa website

Provider tip: Trudhesa Direct can also help with prior authorization support. Their patient access team can assist with insurance appeals and step therapy documentation. Encourage your staff to contact them when prescribing.

Brekiya Savings

Amneal Pharmaceuticals offers savings programs for Brekiya, the newer subcutaneous formulation approved in 2025. Eligible commercially insured patients may pay as little as $40 per carton. Check with the Amneal patient access team for current program details and enrollment.

Patient Assistance Programs for Uninsured or Underinsured Patients

For patients with limited or no insurance coverage, manufacturer patient assistance programs (PAPs) can provide the medication at no cost. These are often underutilized because providers don't know they exist or assume the paperwork isn't worth the effort. It is.

Impel Pharmaceuticals Patient Assistance Program (Trudhesa)

Available for patients experiencing financial hardship or who have limited or no insurance. Patients or their providers can call 1-800-589-0841 (option 1) to begin the enrollment process. Documentation of financial need is typically required.

Third-Party Resources

Several nonprofit organizations maintain databases of patient assistance programs that may cover Dihydroergotamine:

• NeedyMeds — Search by drug name for manufacturer and nonprofit assistance programs. needymeds.org
• RxAssist — Comprehensive directory of pharmaceutical patient assistance programs. rxassist.org
• RxHope — Helps patients and providers locate medication assistance programs. rxhope.com

Provider tip: Consider designating a staff member as your practice's "savings navigator" who can run through these resources when a patient reports cost concerns. A five-minute search can save a patient hundreds of dollars per month.

Discount Cards and Coupon Programs

For the generic injectable form of Dihydroergotamine, pharmacy discount cards can significantly reduce the cash price. These are especially useful for uninsured patients or those whose insurance doesn't cover DHE.

• GoodRx: Can reduce generic DHE injection to approximately $260–$400
• SingleCare: Comparable savings on generic formulations at participating pharmacies
• RxSaver and Optum Perks: Worth comparing for best local pricing, as prices vary by pharmacy

For a detailed breakdown of all available discount programs, see our patient-facing guide: How to Save Money on Dihydroergotamine.

Important note: Discount cards generally do not work with insurance. They are an alternative to insurance pricing, not supplemental. Patients should compare their insurance copay against the discount card price and use whichever is lower.

Generic Alternatives and Therapeutic Substitution

When cost is the primary barrier, consider whether the patient's current DHE formulation is the most cost-effective option for their clinical situation.

Within DHE Formulations

The generic injectable form is the least expensive DHE option when paired with a discount card. If your patient is currently on Trudhesa or Migranal and struggling with cost, switching to generic injectable DHE for subcutaneous self-administration may be appropriate — though this requires teaching the injection technique and confirming the patient is comfortable with needles.

Therapeutic Alternatives

If DHE is not feasible due to cost or availability (there is an active shortage of the injection form), several therapeutic alternatives may work depending on the clinical scenario. For a comprehensive list, see Alternatives to Dihydroergotamine.

• Sumatriptan injection (generic): Often available for $30–$80 with discount cards. First-line for many patients and significantly cheaper than DHE.
• Ubrogepant (Ubrelvy) or Rimegepant (Nurtec ODT): CGRP receptor antagonists for acute migraine. No vasoconstrictive effects, safer for cardiovascular risk patients. Manufacturer copay programs available.
• Lasmiditan (Reyvow): 5-HT1F receptor agonist. No vasoconstrictive effects. May be an option for patients who need DHE-like efficacy without cardiovascular risk.

For patients specifically on DHE for status migrainosus or refractory migraine who cannot use alternatives, escalating the prior authorization process or pursuing a formulary exception with documentation of medical necessity is often the best path.

Building Cost Conversations Into Your Workflow

Cost-related non-adherence is one of the most common reasons patients stop using DHE. Many patients won't bring up cost concerns unless asked directly. Here are practical ways to integrate cost awareness into prescribing:

1. Ask about cost at every prescribing visit. A simple "Are you having any trouble affording your medications?" opens the door.
2. Check insurance formulary before prescribing. Know whether DHE requires prior authorization or step therapy for the patient's plan. This prevents fill delays and surprise costs.
3. Prescribe the most cost-effective formulation first. Unless clinical factors dictate a specific delivery method, start with generic injectable DHE when possible.
4. Enroll eligible patients in savings programs at the point of prescribing. Don't wait for the patient to hit a cost wall at the pharmacy. Provide the Trudhesa Direct number (1-800-589-0841) or NeedyMeds information before they leave your office.
5. Document prior authorization thoroughly. Include documentation of failed triptan trials, frequency and severity of migraine episodes, and clinical rationale for DHE. This improves approval rates and speeds up the process.

Navigating the DHE Shortage

Adding to the cost challenge, Dihydroergotamine injection has been in intermittent shortage since 2017. Perrigo has discontinued its generic DHE injection, and Sandoz is the primary remaining manufacturer. When supply is limited, prices increase and patients may need to call multiple pharmacies. For a detailed breakdown of the shortage situation, see our provider shortage update.

Consider helping patients check pharmacy availability proactively. Tools like Medfinder can help patients and providers locate pharmacies that currently have DHE in stock.

Insurance Tips: Prior Authorization and Appeals

Most insurance plans that cover DHE require prior authorization, and many require step therapy (documented failure of at least one triptan). Here's how to streamline the process:

• Document everything: Previous treatments tried and failed, migraine frequency/severity, impact on daily functioning
• Use manufacturer PA support: Trudhesa's patient access team provides PA templates and can assist with appeals
• Appeal denials: First-level denials are frequently overturned. Include peer-reviewed literature supporting DHE efficacy for the patient's specific condition.
• Medicare Part B vs. Part D: Part B may cover injectable DHE when administered in-office. Part D covers self-administered forms. Know which applies to your patient.

Quick Reference: Savings Options at a Glance

Here's a summary of the key savings options to keep handy:

• Trudhesa Direct: $0 copay for eligible commercially insured patients (1-800-589-0841)
• Brekiya Savings: As low as $40/carton for eligible patients
• Generic DHE + GoodRx: $260–$400 for injection form
• Impel PAP: Free Trudhesa for qualifying uninsured/underinsured patients
• Sumatriptan (generic): $30–$80 as a lower-cost therapeutic alternative

Final Thoughts

Dihydroergotamine is a uniquely effective medication for severe and refractory migraine — but its cost and availability challenges mean patients need active support from their providers. A few minutes spent on savings enrollment or formulation optimization at the point of prescribing can be the difference between a patient staying on an effective treatment or abandoning it. For tools to help your patients find DHE in stock and navigate affordability, visit Medfinder for Providers.